Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand

Experimental Eye Research

Volumn 80, Issue 3, 2005, Pages 435-442

  Sarayba, Melvin A ^a   Li, Li ^a   Tungsiripat, Tulaya ^a   Liu, Norman H ^a   Sweet, Paula M ^a   Patel, Anup J ^a   Osann, Kathryn E ^b   Chittiboyina, Amar ^c   Benson, Stephen C ^d   Pershadsingh, Harrihar A ^a   Chuck, Roy S ^a,e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

^e University of California at Irvine   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cornea; Neovascularization; Pioglitazone; PPAR; Thiazolidinediones

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; IMAGING SYSTEM; INHIBITION KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 13844294425     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2004.10.009     Document Type: Article

References (36)

1. P. Aoun, J.W. Simpkins, and N. Agarwal Role of PPAR-γ ligand in neuroportection against glutamate-induced cytotoxicity in retinal ganglion cells Invest. Ophthalmol. Vis. Sci. 44 2003 2999 3004
2. U. Benelli, J.R. Ross, M. Nardi, and G.K. Klintworth Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A Invest. Ophthalmol. Vis. Sci. 38 1997 274 282
3. S. Benson, J. Wu, S. Padmanabhan, T.W. Kurtz, and H.A. Pershadsingh Peroxisome proliferator-activated receptor (PPAR) gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the PPAR-gamma activator troglitazone Am. J. Hypertens. 13 2000 74 82
4. 2,14-PGJ2, but not troglitazone, modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways FEBS Lett. 501 2001 24 30
5. J.H. Chang, E.E. Gabison, T. Kato, and D.T. Azar Corneal neovascularization Curr. Opin. Ophthalmol. 12 2001 242 249
6. M.B. Debril, J.P. Renaud, L. Fajas, and J. Auwerx The pleiotropic functions of peroxisome proliferator-activated receptor-gamma J. Mol. Med. 79 2001 30 47
7. P. Delerive, J.C. Fruchart, and B. Staels Peroxisome proliferator- activated receptors in inflammation control J. Endocrinol. 169 2001 453 459
8. C.N. Ellis, J. Varani, G.J. Fisher, M.E. Zeigler, H.A. Pershadsingh, S.C. Benson, Y. Chi, and T.W. Kurtz Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-γ inhibit keratinocyte proliferation Arch. Dermatol. 136 2000 609 616
9. H. Ghanim, R. Garg, A. Aljada, P. Mohanty, Y. Kumbkarni, E. Assian, W. Hamouda, and P. Dandona Suppression of nuclear factor-κB and stimulation of inhibitor-κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese J. Clin. Endocrinol. Metab. 86 2001 1306 1312
10. C.K. Glass Potential roles of the peroxisome proliferator-activated receptor-γ in macrophage biology and atherosclerosis J. Endocrinol. 169 2001 461 464
11. Y. Hattori, K. Akimoto, and K. Kasai The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II Biochem. Biophys. Res. Commun. 273 2000 1144 1149
12. C. Jiang, A.T. Ting, and B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
13. B.M. Kenyon, E.E. Voest, C.C. Chen, E. Flynn, J. Folkman, and R.J. D'Amato A model of angiogenesis in the mouse cornea Invest. Ophthalmol. Vis. Sci. 37 1996 1625 1631
14. S.A. Kliewer, H.E. Xu, M.H. Lambert, and T.M. Willson Peroxisome proliferator-activated receptors: from genes to physiology Recent Prog. Horm. Res. 56 2001 239 263
15. v-integrin antagonists in the rat Graefes Arch. Clin. Exp. Ophthalmol. 238 2000 88 93
16. H. Koshiyama, D. Shimono, N. Kuwamura, J. Minamikawa, and Y. Nakamura Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes J. Clin. Endocrinol. Metab. 86 2001 3452 3456
17. C.M. Lai, M. Brankov, T. Zaknich, Y.K. Lai, W.Y. Shen, I.J. Constable, I. Kovesdi, and P.E. Rakoszy Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization Hum. Gene Ther. 12 2001 1299 1310
18. P. Lee, C.C. Wang, and A.P. Adamis Ocular neovascularization: an epidemiologic review Surv. Ophthalmol. 43 1998 245 269
19. P.F. Lopez, B.D. Sippy, H.M. Lambert, A.B. Thach, and D.R. Hinton Transdifferentiated RPE cells and VEGF immunoreactivity in surgically-excised ARMD-related choroidal neovascular membranes Invest. Ophthalmol. Vis. Sci. 37 1996 855 868
20. 2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression Diabetes 49 2000 346 355
21. N. Marx, G. Sukhova, C. Murphy, P. Libby, and J. Plutzky Macrophages in human atheroma contain PPARγ: differentiation-dependent PPARγ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro Am. J. Pathol. 153 1998 17 23
22. T. Murata, S. He, M. Hangai, T. Ishibashi, X.P. Xi, S. Kim, W.A. Hsueh, S.J. Ryan, R.E. Law, and D.R. Hinton Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization Invest. Ophthalmol. Vis. Sci. 41 2000 2309 2317
23. T. Murata, Y. Hata, T. Ishibashi, S. Kim, W.A. Hsueh, R.E. Law, and D.R. Hinton Response of experimental retinal neovascularization to thiazolidinediones Arch. Ophthalmol. 119 2001 709 717
24. D. Panigrahy, S. Singer, L.Q. Shen, C.E. Butterfield, D.A. Freedman, E.J. Chen, M.A. Moses, S. Kilroy, S. Duensing, C. Fletcher, J.A. Fletcher, L. Hlatky, P. Hahnfeldt, J. Folkman, and A. Kaipainen PPAR-gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis J. Clin. Invest. 110 2002 923 932
25. H.A. Pershadsingh Pharmacological peroxisome proliferator-activated receptor γ ligands: emerging clinical indications beyond diabetes Expert Opin. Investig. Drugs 8 1999 1859 1872
26. H.A. Pershadsingh, S.C. Benson, B. Marshall, T.W. Kurtz, M. Pravenec, J.C. King, E.G. Stopa, and E.V. Famiglietti Ocular diseases and peroxisome proliferator-activated receptor-gamma (PPARγ) in mammalian eye. Society for Neuroscience, 29th Annual Meeting, Miami Beach, FL 1999
27. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
28. W. Risau Mechanisms of angiogenesis Nature 386 1997 671 674
29. D.S. Straus, and C.K. Glass Cyclopentenone prostaglandins: new insights on biological activities and cellular targets Med. Res. Rev. 21 2001 185 210
30. C.G. Su, and J.D. Lewis Antineoplastic and anti-inflammatory effects of PPAR ligands in colitis Gastroenterology 21 2001 1019 1021
31. P.F. Torres, and A. Kijlstra The role of cytokines in corneal immunopathology Ocul. Immunol. Inflamm. 9 2001 9 24
32. K. Wada, A. Nakajima, and R.S. Blumberg PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease Trends Mol. Med. 7 2001 329 331
33. T.M. Willson, M.H. Lambert, and S.A. Kliewer Peroxisome proliferator-activated receptor-gamma and metabolic disease Annu. Rev. Biochem. 70 2001 341 367
34. X. Xin, S. Yang, J. Kowalski, and M.E. Gerritsen Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo J. Biol. Chem. 74 1999 9116 9121
35. X.Y. Yang, L.H. Wang, T. Chen, D.R. Hodge, J.H. Resau, L. DaSilva, and W.L. Farrar Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARγ) agonists. PPARγ co-association with transcription factor NFAT J. Biol. Chem. 275 2000 4541 4544
36. M. Zheng, M.A. Schwarz, S. Lee, U. Kumaraguru, and B.T. Rouse Control of stromal keratitis by inhibition of neovascularization Am. J. Pathol. 159 2001 1021 1029